Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Bayer AG by Year
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M)
Merck Bayer AG: $153M in FY2021. No newer figure appears in the documents we track.
Latest, FY2021
153
Period ended Dec 31, 2021
Change on a year earlier
–
History
1 years
Since FY2021
Sources
1
Form 10-K (filed 2024-02-26)
Where the FY2021 figure comes from
Source: Form 10-K (filed 2024-02-26) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 153 | – | Form 10-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck Bayer AG ($M), annual FY2021–FY2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-bayer-amort
See every metric in the Merck KPI table. Data updated Oct 26, 2026.